我院门诊老年冠心病患者抗血小板药物的应用调查与分析

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the use of antiplatelet drugs in elderly outpatients with coronary heart disease in our hospital.Methods Altogether 100 prescriptions were randomly extracted from elderly outpatients with coronary heart disease every month from January to December 2018 and a total of 1200 prescriptions were selected for investigation analysis.Then the use of antiplatelet drugs was counted and analyzed.Results The percentage of the use of Aluminum Magnesium Aspirin, Aspirin, Clopidogrel and Ticagrelor was 5.67%, 53.67%, 23.67% and 0.67%, respectively.Among them, antiplatelet drugs were used in 848 prescriptions (70.67%), including 148 prescriptions (12.33%) for two antiplatelet drugs used and 700 prescriptions (58.33%) for one antiplatelet drug used.The most frequently prescribed antiplatelet drugs were Aspirin and Clopidogrel.Meanwhile, 12 unreasonable prescriptions (1.00%) were found in this study and all the unreasonable prescriptions were accounted for adverse drug interactions between Clopidogrel and proton pump inhibitors.Conclusion The proportion of antiplatelet drugs used in elderly outpatients with coronary heart disease in our hospital is relatively high and the traditional antiplatelet drug (Aspirin) is still the main used drug.The use of antiplatelet drugs is basically reasonable, but more attention to drug interactions between Clopidogrel and proton pump inhibitors should be paid.

Key words： Coronary heart disease Antiplatelet drugs Dual antiplatelet therapy Thromboxane A2 inhibitors Adenosine diphosphate P2Y12 receptor antagonists

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FANG Hai-yan
	CHEN Li-xin

Cite this article:

FANG Hai-yan,CHEN Li-xin. Investigation and analysis of antiplatelet drugs used in elderly outpatients with coronary heart disease in our hospital[J]. 中国当代医药, 2020, 27(13): 173-176.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I13/173

[1]	刘小清.冠心病流行病学研究进展及疾病负担[J].中华心血管病杂志，2008，36（6）：573-576.
[2]	Gulizia MM，Colivicchi F，Abrignani MG，et al.Consensus document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA：Long-term antiplatelet therapy in patients with coronary artery disease[J].Eur Heart J Suppl，2018，20（Suppl F）：F1-F74.
[3]	国家卫生计生委合理用药专家委员会，中国药师协会.冠心病合理用药指南（第2 版）[J].中国医学前沿杂志（电子版），2018，10（6）：1-130.
[4]	王萍.老年冠心病患者的抗血小板药物应用现状[J].现代诊断与治疗，2017，28（19）：3558-3560.
[5]	南京，彭建军.抗血小板药物的研究进展[J].中华老年心脑血管病杂志，2017，19（1）：92-93.
[6]	司晓凤，陶贵周.抗血小板药物在冠心病中的临床应用进展[J].医学与哲学，2018，39（12）：48-50，74.
[7]	葛均波，徐永健，王辰，等.内科学[M].北京：人民卫生出版社，2018：218-234.
[8]	阎文龙.冠心病的流行病学调查研究[D].长春：长春中医药大学，2018.
[9]	严激.冠心病流行病学变迁的启示[C].//岭南心血管病杂志编辑部.第14 届中国南方国际心血管病学术会议论文集.2012：78-82.
[10]	何忠建.老年冠心病患者抗血小板治疗的临床研究[J].实用临床医药杂志，2016，20（21）：172-173.
[11]	Ben-Dor I，Kleiman NS，Lev E.Assessment, mechanisms,and clinical implication of variability in platelet response to aspirin and clopidogrel therapy[J].Am J Cardiol，2009，104（2）：227-233.
[12]	Antithrombotic Trialists′ Collaboration.Collaborative metaanalysis of randomized trials of antiplatelet therapy of prevention of death，myocardial infraction，and stroke in high risk patients[J].BMJ，2002，324（7330）：141.
[13]	Campbell CL，Smyth S，Montalescot G，et al.Aspirin dose for the prevention of cardiovascular disease：a systematic review[J].JAMA，2007，297（18）：2018-2024.
[14]	中国老年学学会心脑血管病专业委员会，中国康复医学会心脑血管病专业委员会.稳定性冠心病口服抗血小板药物治疗中国专家共识[J].中华心血管病杂志，2016，44（2）：104-111.
[15]	中华医学会心血管病学分会，中华心血管病杂志编辑委员会.抗血小板治疗中国专家共识[J].中华心血管病杂志，2013，41（3）：183-194.
[16]	张邑，杜春丽，刘小燕，等.阿司匹林铝镁合剂对冠心病患者抗血小板聚集的有效性与安全性评价[J].中国药业，2011，20（17）：18-19.
[17]	刘凯.冠心病特殊人群抗血小板治疗策略[J].医学综述，2016，22（9）：1719-1723.
[18]	拓永东，陈庆岭，徐慧峰，等.142 例老年冠心病患者应用阿司匹林治疗的调查[J].解放军保健医学杂志，2005，7（4）：231-232.
[19]	付梦璐，董若兰，凃玲，等.氯吡格雷抵抗研究进展[J].医药导报，2018，37（2）：139-145.
[20]	中国医师协会心血管内科医师分会血栓防治专业委员会，中华医学会心血管病学分会介入学组，中华心血管病杂志编辑委员会.替格瑞洛临床应用中国专家共识[J].中华心血管病杂志，2016，44（2）：112-120.